Article Text

Download PDFPDF

2022-RA-1439-ESGO Is it time to perform radiochemotherapy and brachytherapy for cervical tumors higher than 3 cm?
Free
  1. Abel Cordoba1,
  2. Benjamin Serouart2,
  3. Emilie Bogart3,
  4. Marie Cécile Le Deley3,
  5. Carlos Martinez Gomez2,
  6. Eric Leblanc2,
  7. Delphine Hudry2,
  8. Alexandre Escande1,
  9. Florence Le Tinier1,
  10. Camille Pasquesoone4,
  11. Sophie Taieb5 and
  12. Fabrice Narducci2
  1. 1Academic Radiotherapy Department, Centre Oscar Lambret, Lille, France
  2. 2Surgical Oncology Department, Centre Oscar Lambret, Lille, France
  3. 3Biostatistics Department, Centre Oscar Lambret, Lille, France
  4. 4Pathology Departmen, Centre Oscar Lambret, Lille, France
  5. 5Radiology Department, Centre Oscar Lambret, Lille, France

Abstract

Introduction/Background The objective of this study is to evaluate the survival and describe the recurrence of patients with early stage cervical cancer treated with ‘Schautheim radical hysterectomy’ by minimally invasive surgery (MIS) at the Oscar Lambret Center.

Methodology From 01/1999 to 12/2018, we included all patients managed by minimally invasive surgery at the Oscar Lambret Center for early stage cervical cancer with tumor size < 4 cm (FIGO stage IA1 with emboli at IIA1). The primary endpoint was the 5-year overall and recurrence-free survival rates in these patients. Overall survival (OS) and Disease-Free Survival (DFS) were estimated from the initial biopsy using the Kaplan-Meier method. Hazard ratio (HR) was estimated with 95% confidence interval (CI95%).

Results A total of 239 patients were included. All patients underwent bilateral pelvic lymphadenectomy before radical hysterectomy . Preoperative image adapted brachytherapy (IABT) was performed in 125 patients. The 5-year overall and recurrence-free survival rates were 92% (95% CI 87.4–95%) and 86.9% (95% CI 81.6–90.7%), respectively. The multivariate analysis showed 2 associated factors to risk of recurrence: previous conization (HR = 0.21 (CI95% 0.06–0.70); p=0.01) and tumor size > 30 mm (HR = 2.26 (CI95% 1.08–4.73); p=0.031). We observed 33 recurrences, including 22 deaths due to disease. The recurrence rates were respectively 7.5% for tumor ≤20 mm, 12.9% for tumor between 20–30 mm, and 24.1% for tumor >30 mm.

Conclusion MIS is safe and for tumor size ≤20 mm with a very low rate of local recurrence; for tumors size >30 mm relapse rates are high and should be treated with concomitant radiochemotherapy and brachytherapy. For sizes between 20 and 30 mm, further data are needed to define management recommendations. Previous conization allow us to have a better accuracy regarding the tumor size in order to tailor the treatment.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.